摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-9-cyclopentyl-2-(2-hydroxy-1-phenylethylamino)-5,7,7-trimethyl-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one | 1204831-72-0

中文名称
——
中文别名
——
英文名称
(R)-9-cyclopentyl-2-(2-hydroxy-1-phenylethylamino)-5,7,7-trimethyl-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one
英文别名
9-cyclopentyl-2-[[(1R)-2-hydroxy-1-phenylethyl]amino]-5,7,7-trimethyl-8H-pyrimido[4,5-b][1,4]diazepin-6-one
(R)-9-cyclopentyl-2-(2-hydroxy-1-phenylethylamino)-5,7,7-trimethyl-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one化学式
CAS
1204831-72-0
化学式
C23H31N5O2
mdl
——
分子量
409.531
InChiKey
LBDZRSHUGBESIF-SFHVURJKSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    30
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.52
  • 拓扑面积:
    81.6
  • 氢给体数:
    2
  • 氢受体数:
    6

文献信息

  • [EN] PROTEIN KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉINE KINASE
    申请人:VERTEX PHARMA
    公开号:WO2010008454A1
    公开(公告)日:2010-01-21
    In one aspect, the invention provides compounds of Formula (I) or pharmaceutically acceptable salts thereof. In another aspect, the invention provides methods for treatment of diseases or disorders mediated by a protein kinase, comprising administering a therapeutically effective amount of a compound of this invention.
    在一个方面,该发明提供了式(I)的化合物或其药学上可接受的盐。在另一个方面,该发明提供了治疗由蛋白激酶介导的疾病或障碍的方法,包括给予本发明化合物的治疗有效量。
  • METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS
    申请人:Charrier Jean-Damien
    公开号:US20120271045A1
    公开(公告)日:2012-10-25
    A method of preparing a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and claims. Additionally, the present invention relates to compounds of Structural Formula (I), which are useful as inhibitors of protein kinase.
    一种制备结构式(I)所代表的化合物或其药学上可接受的盐的方法,其中结构式(I)的变量如规范和权利要求所述。此外,本发明涉及结构式(I)的化合物,其作为蛋白激酶抑制剂是有用的。
  • PROTEIN KINASE INHIBITORS
    申请人:Charrier Jean-Damien
    公开号:US20120322793A1
    公开(公告)日:2012-12-20
    In one aspect, the invention provides compounds of Formula I or pharmaceutically acceptable salts thereof. In another aspect, the invention provides methods for treatment of diseases or disorders mediated by a protein kinase, comprising administering a therapeutically effective amount of a compound of this invention.
    在一个方面,本发明提供了公式I的化合物或其药学上可接受的盐。在另一个方面,本发明提供了治疗由蛋白激酶介导的疾病或紊乱的方法,包括给予本发明化合物的治疗有效量。
  • US8278297B2
    申请人:——
    公开号:US8278297B2
    公开(公告)日:2012-10-02
  • US8618106B2
    申请人:——
    公开号:US8618106B2
    公开(公告)日:2013-12-31
查看更多

同类化合物

阿斯普尼辛B 阿斯普尼辛 D 阿斯普尼辛 苯佐莫文 新骏河毒素 乙酰胺,N-(4-硝基-2-吡啶基)-,氧化(9CI) TAK960抑制剂 PLK1抑制剂(RO3280) 8H-嘧啶并[4,5-b][1,4]二氮杂卓 8-甲基-5,9-二氢-6H-嘧啶并[4,5-b][1,4]重氮基庚英-6-酮 6H-嘧啶并[4,5-b][1,4]二氮杂卓 4-甲基-6,11-二氢-3H-嘧啶并[4,5-b][1,5]苯并二氮杂卓-2,5-二酮 2-氯-7,7-二氟-5-甲基-5,7,8,9-四氢-6H-嘧啶基[4,5-B][1,4]二氮杂-6-酮 2-氯-5-甲基-5,7,8,9-四氢-6H-嘧啶[4,5-B][1,4]二氮杂6-酮 1H-嘧啶并[4,5-b][1,4]二氮杂卓 5-(2-piperidin-1-yl-ethyl)-5,11-dihydro-benzo[e]pyrido[3,2-b][1,4]diazepin-6-one 4-oxo-2-pyridin-4-yl-5,6,8,9-tetrahydro-4H-1,4a,7-triaza-benzocycloheptene-7-carboxylic acid ethyl ester 7-chloro-5-phenyl-1-propyl-1,3-dihydro-pyrido[3,2-e][1,4]diazepin-2-one 6-methoxy-8-methyl-4-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)pteridin-7(8H)-one 4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-N-((1S,2R)-2-hydroxycyclohexyl)-3-methoxybenzamide 8-chloro-1,2,3,4-tetrahydro-pyrazino[2,1-b]quinazolin-6-one hydrochloride salt of 3-(2-chlorophenyl)-7-[(1-hydroxymethylcyclohexyl)amino]-1-methyl-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1 H)-one {2-[4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido-[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-benzoylamino]-ethyl}-carbamic acid tert-butyl ester (7R)-8-cyclohexyl-2-[(4-fluoro-1H-indazol-5-yl)amino]-5-(3-fluorophenyl)-7-methyl-7,8-dihydropteridin-6(5H)-one 7-ethoxy-8-ethyl-9-methyl-1(3),7-dihydro-[1,3]diazepino[2,1-i]purin-10-one 3-(((1H-indol-3-yl)methylene)amino)-3,4-dihydroquinazolin-2(1H)-one 3-[[(7R)-7-benzyl-2,5,8,11,14-pentazatricyclo[8.4.0.02,6]tetradeca-1(14),3,5,10,12-pentaen-8-yl]sulfonyl]benzoic acid 5-(hydroxyamino)-11H-pyrimido[4,5-b][1,5]benzodiazepine 3-ethyl-7-(3-piperidin-1-yl-propyl)-7,12-dihydro-3H-benzo[b]pyrazolo[4',3':5,6]pyrido[4,3-e][1,4]diazepin-6-one (7R)-7-benzyl-8-[2-(trifluoromethoxy)phenyl]sulfonyl-2,5,8,12,14-pentazatricyclo[8.4.0.02,6]tetradeca-1(14),3,5,10,12-pentaene 3-(9-ethylamino-6-oxo-2,3,3a,4-tetrahydro-1H,6H-5,8,10,10b-tetraazabenzo[e]azulen-5-yl)benzoic acid-N'-acetyl hydrazide 7-chloro-2-oxo-5-phenyl-2,3-dihydro-pyrido[3,2-e][1,4]diazepine-1-carboxylic acid allylamide 6-(4-bromobenzylidene)-6,11-dihydro-13H-isoquinolino[3,2-b]quinazolin-13-one (+/-)-9-methylamino-4-oxo-2-pyridin-4-yl-5,6,8,9-tetrahydro-4H-1,4a,7-triaza-benzocycloheptene-7-carboxylic acid ethyl ester 5-benzyl-2-(1H-indol-4-yl)-6a,7,9,10-tetrahydro-[1,4]oxazino[3,4-h]pteridin-6(5H)-one 4-{[7-(cyclopropylmethoxy)-5-methyl-6-oxo-8-(3-thienyl)-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl]amino}-3-methyl-N-(1-methylpiperidin-4-yl)benzamide 6-(4-chlorobenzylidene)-6,11-dihydro-13H-isoquinolino[3,2-b]quinazolin-13-one 6-benzylidene-6,11-dihydro-13H-isoquinolino[3,2-b]quinazolin-13-one 6-(4-methoxybenzylidene)-6,11-dihydro-13H-isoquinolino[3,2-b]quinazolin-13-one 6-{[(4-dimethylamino)phenyl]methylidene}-6,11-dihydro-13H-isoquino[3,2-b]quinazolin-13-one 1H-spiro[pyrimido[4,5-b]quinoline-5,5'-pyrrolo[2,3-d]pyrimidine]-2,2',4,4',6'(1'H,3H,3'H,7'H,10H)-pentaone tert-butyl 3-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzamido) azetidine-1-carboxylate 4-deoxy-4-amino-7,10-methano-5-deazapteroic acid (S)-N,N-dimethyl 2-[3-(9-ethylamino-6-oxo-2,3,3a,4-tetrahydro-1H,6H-5,8,10,10b-tetraazabenzo[e]azulen-5-yl)phenyl]-1,3-oxazole-4-carboxamide diethyl (4-{[4-{[7-(hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)-2-methyl-3-oxo-2,3-dihydro-1H-isoindol-4-yl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}benzyl)phosphonate 3-[2-(3-methyl-5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-quinazolin-4-yl]-4-(6H-thieno[2,3-b]pyrrol-4-yl)-pyrrole-2,5-dione 4-((R)-9-cyclopentyl-7-fluoro-5-methyl-6-oxo-7-vinyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-N-((R)-piperidin-3-yl)benzamide (S)-N,N-dimethyl 5-[3-(9-methylamino-6-oxo-2,3,3a,4-tetrahydro-1H,6H-5,8,10,10b-tetraazabenzo[e]azulenyl)phenyl]-1,3,4-oxadiazole-2-carboxamide 4-[(6-cyclopentyl-2,5-dimethyl-3-oxo-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-9-yl)amino]-3-methoxy-N-(1-methyl-4-piperidyl)benzamide